FDA Grants Accelerated Approval to GSK's Neladalkib for Lung Cancer

The U.S. Food and Drug Administration has granted accelerated approval to neladalkib, a kinase inhibitor designed for lung cancer treatment. This therapeutic asset is now part of GSK's oncology portfolio following the company's $10.6 billion acquisition of Nuvalent earlier this year. The approval marks a significant milestone in validating GSK's recent strategic investment in Boston-based biopharma firm Nuvalent. By integrating neladalkib into its pipeline, GSK strengthens its position in the competitive oncology market and expands its specialized lung cancer treatment options.

By https://seekingalpha.com/user/52867120/bio · Seeking Alpha ·

FDA Grants Accelerated Approval to GSK's Neladalkib for Lung Cancer

Tickers: $GSK

Topics: accelerated approval biopharma acquisition lung cancer therapy

Read the full article at Seeking Alpha

More World news